project year

2016

CAPP3: a randomized dose finding non inferiority study of aspirin to prevent cancer in Lynch Syndrome

Defining the cellular determinants that drive dynamin inhibitor induced cell death and in vivo efficacy against glioblastoma

Defining the critical role of osteoclasts in multiple myeloma cell growth and activation in bone

Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer

Developing inhibitors of the LMO4 oncoprotein

EAGLE FM Study: EvaluAtion of Groin Lymphadenectomy Extent For metastatic Melanoma

Gene modified T cells expressing a chimeric antigen receptor for a kappa light chain antigen to treat multiple myeloma

HCC Outcomes mitigation and disease Prevention through Clinical Partnerships (HOPE)

Ibudilast as a treatment for chemotherapy-induced peripheral neuropathies and cognitive impairments

Melanoma Margins Trial: A Phase III, Multi-centre Randomised Controlled Trial

Novel Treatment Targets in Low-Grade Serous Ovarian Cancer

Preventing people with immune deficiencies from developing cancer

Rational Targeting of the Hedgehog Pathway to Treat Osteosarcoma

Targeting Innate Chemoresistance in Lung Adenocarcinoma

The Kay Stubbs Project Grant: Exploring and Exploiting the Epigenetic Basis of Endocrine Resistant Breast Cancer

The Robyn Trinder Project Grant: Starving cancer cells: Developing nutrient uptake inhibitors as prostate cancer therapeutics

VERTU - Veliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma

When the stakes are high: Psychological and behavioural impact of genomic testing for breast cancer risk

Help us to put an end to cancer